The impact of Fc gamma receptor IIa and IIIa gene polymorphisms on the therapeutic response of rituximab in Egyptian adult immune thrombocytopenic purpura

Figures & data

Figure 1. RFLP analysis of FcγRIIa polymorphisms. Lane 1: DNA marker (50–1000 bps). Lanes 5, 7, 8, 10, 11: heterozygous HR (316 bp and 337 bp). Lanes 3, 4, 6, 9: homozygous RR (316 bp). Lane 2: Wild type HH (337 bp).

Figure 2. RFLP analysis of FcγRIIIa polymorphisms. Lane 1: DNA marker (50–1000 bps). Lanes 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12: Wild type FF (94 bp).

Table 1. Platelets count at the end of week 1, week 2, week 3 and week 4 of rituximab.

	Response			P-value
	CR (n = 18)	PR (n = 19)	NR (n = 13)
Platelets at W1
Range	3.0–900.0	6.0–134.0	5.0–40.0	<.001
Mean ± SD	129.9 ± 200.1	49.2 ± 40.1	18.6 ± 10.8
Median	79.0	35.0	15.0
Platelets at W2
Range	22.0–919.0	4.0–100.0	4.0–63.0	<.001
Mean ± SD	149.2 ± 218.8	43.8 ± 26.4	25.0 ± 19.3
Median	57.5	40.0	17.0
Platelets at W3
Range	31.0–437.0	6.0–167.0	4.0–82.0	<.001
Mean ± SD	153.7 ± 123.0	43.2 ± 35.3	30.2 ± 23.7
Median	121.5	36.0	21.0
Platelets at W4
Range	51.0–271.0	7.0–198.0	6.0–70.0
Mean ± SD	143.7 ± 65.6	52.6 ± 41.3	29.9 ± 20.6	<.001
Median	141.5	47.0	25.0

Table 2. The distribution of FcγRIIa-131H/R genotypes according to response to rituximab.

	Response						P-value
	CR (n = 18)		PR (n = 19)		NR (n = 13)
	N	%	N	%	N	%
FcγRIIa results
HH genotype	3	16.7	5	26.3	5	38.5	.648
HR genotype	7	38.9	8	42.1	5	38.5
RR genotype	8	44.4	6	31.6	3	23.1

Table 3. Comparison between the response in both groups regarding FcγRIIa gene polymorphisms.

	Response
	CR
	Group				P-value
	Rituximab		Other lines
	N	%	N	%
FcγRIIa results
HH	3	16.7	9	36.0	.171
HR	7	38.9	11	44.0
RR	8	44.4	5	20.0
	Response
	PR
	Group
	Mapthera		Other lines
	N	%	N	%	P-value
FcγRIIa results
HH	5	26.3	3	16.7	.759
HR	8	42.1	8	44.4
RR	6	31.6	7	38.9
	Response
	NR
	Group
	Mapthera		Other lines
	N	%	N	%	P-value
FcγRIIa results
HH	5	38.5	3	42.9	.903
HR	5	38.5	2	28.6
RR	3	23.1	2	28.6